Under 10% of people eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it issues its inaugural recommendations on the therapies.
Given over a billion individuals worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
Based on forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a lifelong illness that can be managed with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major barriers to widespread availability to the injections that can assist patients in reducing considerable weight, explains the organization.
GLP-1 Therapy Scarcity
Despite the present most optimistic case, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The guideline encourages countries and companies to widen availability, through strategies such as voluntary licensing.
A patent on a key compound – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals eat less.
Individuals usually see weight reduction after several weeks of commencing the once-weekly jabs.
Studies indicates patients may put most of the weight back on a year later of discontinuing the treatment, because their usual food cravings come back.
To be carrying excess weight increases your risk for contracting diseases, including diabetes, heart disease, stroke, and certain malignancies.
Obesity concerns people in all nations and was responsible for millions of deaths worldwide in 2024, as per the WHO.
